Platelet Hyperreactivity Project (PHP)
This study has been completed.
Information provided by (Responsible Party):
Pierre Fontana, University Hospital, Geneva
First received: September 11, 2009
Last updated: December 1, 2015
Last verified: December 2015
The PHP study aims to delineate gene products involved in high on-treatment platelet reactivity in aspirin-treated cardiovascular patients.
||Observational Model: Cohort
Time Perspective: Prospective
||Platelet Hyperreactivity Project: A System Biology Approach of High On-treatment Platelet Reactivity in Aspirin-treated Cardiovascular Patients
Primary Outcome Measures:
Secondary Outcome Measures:
- platelet hyperreactivity phenotype in cardiovascular patients treated with aspirin [ Time Frame: cross sectional ] [ Designated as safety issue: No ]
Biospecimen Retention: Samples With DNA
Other Outcome Measures:
- genetic polymorphisms associated with platelet hyperreactivity [ Time Frame: cross sectional ] [ Designated as safety issue: No ]
Plasma Serum Platelets
| Study Start Date:
| Study Completion Date:
| Primary Completion Date:
||January 2010 (Final data collection date for primary outcome measure)
The PHP study aims to delineate gene products involved in high on-treatment platelet reactivity in aspirin-treated cardiovascular patients using a system biology approach that include proteomics analysis of selected platelet sub-fractions in patients displaying extreme phenotype.
- to characterize the proteome profile of platelet hyperreactivity in aspirin-treated cardiovascular patients
- to characterize the platelet hyperreactivity phenotype in cardiovascular patients treated with aspirin
- to determine genetic polymorphisms associated with platelet hyperreactivity
|Ages Eligible for Study:
||18 Years to 99 Years (Adult, Senior)
|Genders Eligible for Study:
|Accepts Healthy Volunteers:
Symptomatic atherothrombotic patients treated with aspirin.
- Documented symptomatic ischemic atherothrombotic disease treated by aspirin.
- Known platelet disorder
- Chronic treatment by antiplatelet drugs other than aspirin
- Chronic anticoagulant treatment
- Chronic non steroidal anti-inflammatory drug treatment
- Active cancer
- Treatment with serotonin reuptake inhibitors
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00976196
|University Hospital Geneva
|Geneva, Switzerland, 1205 |
||Pierre Fontana, MD, PhD
||University of Geneva
||Pierre Fontana, PI, University Hospital, Geneva
History of Changes
|Other Study ID Numbers:
|Study First Received:
||September 11, 2009
||December 1, 2015
||Switzerland: Federal Office of Public Health
Keywords provided by University Hospital, Geneva:
Additional relevant MeSH terms:
ClinicalTrials.gov processed this record on August 25, 2016
Anti-Inflammatory Agents, Non-Steroidal
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Fibrin Modulating Agents
Molecular Mechanisms of Pharmacological Action
Platelet Aggregation Inhibitors